Camptothecin

HCID 24360CAS 7689-03-4

Grundinformationen

Standard-SMILES
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
InChIKey
VSJKWCGYPAHWDS-FQEVSTJZSA-N
Summenformel
C20H16N2O4
Durchschnittliche Molmasse
348,4 g/mol
Monoisotopische Masse
348,11100699

Überblick

Camptothecin is a pyranoindolizinoquinoline that is pyrano[3',4':6,7]indolizino[1,2-b]quinoline which is substituted by oxo groups at positions 3 and 14, and by an ethyl group and a hydroxy group at position 4 (the S enantiomer). It has a role as an antineoplastic agent, an EC 5.99.1.2 (DNA topoisomerase) inhibitor, a genotoxin and a plant metabolite. It is a delta-lactone, a quinoline alkaloid, a tertiary alcohol and a pyranoindolizinoquinoline.

Namen und Bezeichner

Bevorzugter Name
Camptothecin
IUPAC
(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
Englischer Name
(+)-Camptothecin
Summenformel
C20H16N2O4
Molmasse
348.35

Namen und Synonyme

camptothecinCamptothecine7689-03-4(S)-(+)-Camptothecin(+)-Camptothecind-Camptothecin20(S)-Camptothecine(+)-Camptothecine21,22-Secocamptothecin-21-oic acid lactoneNSC94600NSC-94600DTXSID0030956
Weitere Namen anzeigen
CaMpathecin(20S)-CAMPTOTHECIN5,6-DIHYDROXY-7-GLUCURONOSYLFLAVONECAMPTOTHECIN, CAMPTOTHECA ACUMINATA1,6-DIHYDROXY-7-GLUCURONOSYLFLAVONECS-1388
(4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dioneXT3Z54Z28A(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dioneCHEBI:276561H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-(4S)-4-ETHYL-4-HYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo(11.8.0.02,11.04,9.015,20)henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-

Datenbank-Bezeichner

CAS
7689-03-4
PubChem CID
24360
DTXSID
DTXSID0030956
ChEMBL
CHEMBL65
ChEBI
CHEBI:27656
UNII
XT3Z54Z28A
EC Number
444-280-6、616-407-7
Nikkaji
J2.266G

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1
Polarare Oberfläche (TPSA)
79,7 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
1
Schwere Atome
26

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antibiotics

Melting Point275-277 °C
Collision Cross Section · 2 Einträge

178.35 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

181.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
260 °C · 260 °C (dec.)(lit.)
Siedepunkt
482.73 °C · 482.73°C (rough estimate)
Dichte
1.3112 · 1.3112 (rough estimate)
Brechungsindex
1.57 · 1.5700 (estimate)
storage temp.
2 · 2-8°C
Löslichkeit
4 · chloroform/methanol (4:1): 4 mg/mL

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 6 Einträge

Danger

H301 (98%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 50 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Danger

H301 (97.1%): Toxic if swallowed [Danger Acute toxicity, oral]

Gefahrenhinweise

Regulatory InformationStatus: Active Update: 10-11-2008 https://echa.europa.eu/registration-dossier/-/registered-dossier/4979
Hazard Classes and Categories · 2 Einträge

Acute Tox. 3 (98%)

Acute Tox. 3 (97.1%)

Sicherheitsdaten

wgk
3
ridadr
UN 1544 6.1/PG 3
hs_code
29399990
RTECS-Nr.
UQ0492000
risk_code
36/37/38-25-20/21/22
hazard_code
T,Xi,Xn

Chemie und Industrie

Pharmakologische Informationen

Pharmacodynamics · 1 Eintrag

Camptothecin demonstrated strong anticancer activity in preliminary clinical trials but also low solubility and adverse drug reaction. Camptothecin is believed to be a potent topoisomerase inhibitor that interferes with the essential function of topoisomerase in DNA replication.

Mechanism of ActionCamptothecin binds to the topoisomerase I and DNA complex resulting in a ternary complex, stabilizing it and preventing DNA re-ligation and therefore causes DNA damage which results in apoptosis.
MeSH Pharmacological Classification · 2 Einträge

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Compounds that inhibit the activity of DNA TOPOISOMERASE I.

Anwendungen · 3 Einträge

BeschreibungCamptothecin is an alkaloid derived from Xi Shu (Camptotheca acuminata), which belongs to Nyssaceae. The traditional Chinese medicine Camptotheca acuminata (Xi Shu) has been collected in the Compilation of Chinese Herbal Medicine, Chinese Materia Medica, and Great Dictionary of Chinese Medicine. Camptotheca acuminata (Xi Shu) is widely distributed in the basin of Yangtze river and the southwestern provinces. The main medicinal parts of Camptotheca acuminata (Xi Shu) are root bark and fruit, which get rid of heat and toxic materials and eliminate the disease.

HistoryIn 1966, Wall M E et al. from the United States isolated an alkaloid from Camptotheca acuminata and defined its chemical structure. The invitro anticancer tests revealed the anticancer activity of the tryptophan-terpene alkaloid, which is known as camptothecin and received widely concern. In 1975, Corey etal. first opened the door for the chiral synthesis of camptothecin, but the reaction step was long and the yield rate was very low. It was not until 1997 that Ciufolini etal. developed a new method for the synthesis of camptothecin by five steps, with a total yield rate up to 51%. The great breakthrough in the chemical synthesis of camptothecin has made its extensive application become a reality.Hydroxycamptothecin, as a camptothecin derivative with a hydroxyl group on the tenth carbon atom, is widely used for the treatment of various cancers. In 1969, researchers from Shanghai Institute of Materia Medica found that hydroxycamptothecin possessed potent anticancer activity and low toxicity. And this finding promoted the production and clinical application of hydroxycamptothecin, but its usage was interrupted for technology and quality. In the 1980s, hydroxycamptothecin was reproduced for clinical application with an improvement in producing technology, and hydroxycamptothecin got its approval number in 1986 for clinical usage in China. In the 1990s, the US Food and Drug Administration approved the clinical application of topotecan and irinotecan, which played a significant role in the prevention and treatment of cancers.

VerwendenAntitumor alkaloid. Binds irreversible to the DNA-topoisomerase I complex, inhibiting the reassociation of DNA after cleavage by topoisomerase I and traps the enzyme in a covalent linkage with DNA. A cytotoxic antitumor agent

Anbieter50 Anbieter

北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
上海如吉生物科技发展有限公司+86-21-65211385-8001 36031160 · [email protected]
Shaanxi Huike Botanical Development Co., Ltd+86-29-62663046 · [email protected]

Ergänzende Hinweise

DefinitionChEBI: A pyranoindolizinoquinoline that is pyrano[3',4':6,7]indolizino[1,2-b]quinoline which is substituted by oxo groups at positions 3 and 14, and by an ethyl group and a hydroxy group at position 4 (the S enantiomer).

Zugehörige Reaktionen

62

Verknüpfte Notizen

Wird geladen…